drugset / Trial / NCT02179359

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

Timeline

Start
2014-09-02
Primary completion
2024-11-21
Completion
2024-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic
Subject Alemtuzumab Monoclonal antibody
Subject Busulfan Small molecule
Subject Cyclophosphamide Other / unclassified
Subject Fludarabine Small molecule